Cullinan Therapeutics Inc
Company Profile
Business description
Cullinan Therapeutics Inc is a clinical-stage biopharmaceutical company developing therapies for autoimmune diseases and cancer. Its development pipeline comprises the following drug candidates: CLN-978, a CD19xCD3 bispecific T cell engager that is being developed for autoimmune diseases; CLN-049, a FLT3xCD3 bispecific T cell engager being evaluated in an ongoing clinical trial in patients with relapsed/refractory acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS); Velinotamig, a BCMAxCD3 bispecific T cell engager being developed to counter autoimmune diseases; and Zipalertinib, being developed as a treatment for non-small cell lung cancer. Additionally, the company is developing several preclinical programs in autoimmune diseases and oncology.
Contact
One Main Street
Suite 1350
CambridgeMA02142
USAT: +1 617 410-4650
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
109
Stocks News & Analysis
stocks
Alphabet raises $80 billion for AI efforts
stocks
SpaceX: What investors need to know about its enormous upcoming IPO
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,017.20 | 3.10 | -0.03% |
| CAC 40 | 8,209.09 | 62.50 | 0.77% |
| DAX 40 | 25,124.17 | 121.13 | 0.48% |
| Dow JONES (US) | 51,307.79 | 228.91 | 0.45% |
| FTSE 100 | 10,373.51 | 34.56 | 0.33% |
| HKSE | 25,622.28 | 416.04 | -1.60% |
| NASDAQ | 27,093.90 | 7.09 | 0.03% |
| Nikkei 225 | 68,402.13 | 1,667.89 | 2.50% |
| NZX 50 Index | 13,115.08 | 55.63 | -0.42% |
| S&P 500 | 7,609.78 | 9.82 | 0.13% |
| S&P/ASX 200 | 8,785.70 | 5.90 | 0.07% |
| SSE Composite Index | 4,085.58 | 10.48 | 0.26% |